The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Daiichi Sankyo's 2012 sales performance.
Deal for experimental antibody drug conjugate could reach $6bn. AstraZeneca (AZ) has invested up to $6bn in a new partnership with Japanese pharma company Daiichi Sankyo (Daiichi) for the development of ... We are delighted to enter this new
Aside from Merck, Zymeworks has inked deals with a number of major pharma companies, including Eli Lilly, Celgene, GlaxoSmithKline and Daiichi Sankyo.
Antibody drug conjugate gained approval in US in December. The European Medicines Agency (EMA) has accelerated the assessment of Daiichi Sankyo and AstraZeneca’s HER2-positive breast cancer candidate, fast-tracking ... Trastuzumab deruxtecan is central
10. Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) is also an ADC that targets HER2.
If approved will compete with AZ/Daiichi Sankyo's Enhertu. Seattle Genetics has scored a US Food and Drug Administration (FDA) priority review for its oral HER2 inhibitor tucatinib in breast ... If Seattle does gain approval for tucatinib, it will go on
Founded in 2015, Windrose Consulting Group is a privately-held global strategy firm that partners with life science companies to maximize...